MedTrace Logo

A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers

NCT02804399 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2019-01-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to estimate the effect of rifampin on the single dose PK of PF-06463922.

Conditions

  • Healthy

Interventions

DRUG

PF-06463922

100 mg oral dose on day 1 in period 1 and on day 8 in period 2

DRUG

rifampin

600 mg QD from day 1 to day 12 in period 2.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02804399 on ClinicalTrials.gov